Ionizable Lipids with Optimized Linkers Enable Lung-Specific, Lipid Nanoparticle-Mediated mRNA Delivery for Treatment of Metastatic Lung Tumors
ACS Nano · 18.02.2025 · 19 (6) · 6571-6587
DOI: 10.1021/acsnano.4c18636 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Nano, online erschienen am 06.02.2025. Verfasst von Gonna Somu Naidu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Precision Nanomedicine, Shmunis School of Biomedicine and Cancer Research, Tel Aviv University, Tel Aviv-Yafo 69978, Israel. Hauptthemen laut MEDLINE: Lung Neoplasms, Nanoparticles, RNA, Messenger, Lipids. Die Arbeit wurde bisher 79-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Research Council, Israel Science Foundation, H2020 Health.
Abstract (Originalsprache)
Lipid nanoparticles (LNPs) have emerged as a groundbreaking delivery system for vaccines and therapeutic mRNAs. Ionizable lipids are the most pivotal component of LNPs due to their ability to electrostatically interact with mRNA, allowing its encapsulation while concurrently enabling its endosomal escape following cellular internalization. Thus, extensive research has been performed to optimize the ionizable lipid structure and to develop formulations that are well tolerated and allow efficient targeting of different organs that result in a high and sustained mRNA expression. However, one facet of the ionizable lipids' structure has been mostly overlooked: the linker segment between the ionizable headgroup and their tails. Here, we screened a rationally designed library of ionizable lipids with different biodegradable linkers. We extensively characterized LNPs formulated using these ionizable lipids and elucidated how these minor structural changes in the ionizable lipids structure radically influenced the LNPs' biodistribution in vivo. We showed how the use of amide and urea linkers can modulate the LNPs' pKa, resulting in an improved specificity for lung transfection. Finally, we demonstrated how one of these lipids (lipid 35) that form LNPs entrapping a bacterial toxin [pseudomonas exotoxin A (mmPE)] in the form of an mRNA reduced tumor burden and significantly increased the survival of mice with lung metastasis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Precision Nanomedicine, Shmunis School of Biomedicine and Cancer Research, Tel Aviv University, Tel Aviv-Yafo 69978, Israel.
- Department of Materials Sciences and Engineering, Tel Aviv University, Tel Aviv-Yafo 69978, Israel.
- Center for Nanoscience and Nanotechnology, Tel Aviv University, Tel Aviv-Yafo 69978, Israel.
- Cancer Biology Research Center, Tel Aviv University, Tel Aviv-Yafo 69978, Israel.
- Department of Pharmaceutical Sciences, University of Padova, Padova 35131, Italy.
ORCID-Profile: Gonna Somu Naidu, Dan Peer
Förderung
- European Research Council
- Israel Science Foundation
- H2020 Health
- H2020 European Research Council
Zitieren
APA
Somu Naidu, G., Rampado, R., Sharma, P., Ezra, A., Kundoor, G. R., Breier, D., & Peer, D. (2025). Ionizable Lipids with Optimized Linkers Enable Lung-Specific, Lipid Nanoparticle-Mediated mRNA Delivery for Treatment of Metastatic Lung Tumors. ACS Nano, 19(6), 6571-6587. https://doi.org/10.1021/acsnano.4c18636
Vancouver
Somu Naidu G, Rampado R, Sharma P, Ezra A, Kundoor GR, Breier D, et al. Ionizable Lipids with Optimized Linkers Enable Lung-Specific, Lipid Nanoparticle-Mediated mRNA Delivery for Treatment of Metastatic Lung Tumors. ACS Nano. 2025;19(6):6571-6587. doi:10.1021/acsnano.4c18636
BibTeX
@article{SomuNaidu2025,
author = {Somu Naidu, Gonna and Rampado, Riccardo and Sharma, Preeti and Ezra, Assaf and Kundoor, Govinda Reddy and Breier, Dor and Peer, Dan},
title = {Ionizable Lipids with Optimized Linkers Enable Lung-Specific, Lipid Nanoparticle-Mediated mRNA Delivery for Treatment of Metastatic Lung Tumors},
journal = {ACS Nano},
year = {2025},
volume = {19},
number = {6},
pages = {6571--6587},
doi = {10.1021/acsnano.4c18636}
}
EUVIMED